echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Youzhiyou Bio-PD-L1/TGF-β double antibody Y101D was approved for clinical use

    Youzhiyou Bio-PD-L1/TGF-β double antibody Y101D was approved for clinical use

    • Last Update: 2021-07-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On May 17, Friendship Bio-PD-L/TGF-β double antibody Y101D was approved by clinical tacit approval, and its indications are locally advanced or metastatic tumors
    .
    It is understood that this is the fourth bispecific antibody new drug developed by Friends of Zhiyou after M802, M701 and Y150


    .


    Immunotherapy is one of the most promising treatment methods for tumors
    .
    PD-1/PD-L1 monoclonal antibody has attracted much attention because of its broad anti-cancer spectrum, long-lasting efficacy, and easy tolerability of side effects, but its response rate is limited to about 20% of tumor patients


    .


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.